Obesity: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 172
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

24 of 30+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  The role of Aiolos in lung-resident CD8+ memory T cell programming.

  Ohio State University· Columbus, United States· US$45,821 awarded in fiscal year 2026· until Oct 2030

• NIH NICHD · F32

  Role of the Placental Intrinsic Clock as a Central Regulator of Endocrine Function and Offspring Growth

  University of Minnesota· Minneapolis, United States· US$76,300 awarded in fiscal year 2026· until Jun 2029

• NIH NIAID · F31

  Dysregulation of Aging Regulatory T-Cell Response in Autoimmune Disease

  Utah State Higher Education System--University of Utah· Salt Lake City, United States· US$38,914 awarded in fiscal year 2026· until Oct 2029

• NIH NIA · R01

  The effects of sleep and diet on glial function

  Texas A&m University· College Station, United States· US$527,686 awarded in fiscal year 2026· until May 2031

• NIH NIDDK · RC2

  Interorgan Genomic Atlas for Discovery of Bioenergetic Dynamics and Mechanisms of Time-Restricted Feeding

  Northwestern University· Chicago, United States· US$1,641,136 awarded in fiscal year 2026· until Jun 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Studying the role of Tbx-3 expressing neurons during obesity and ageing (OBrAgeing)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €226,421· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Selective Sensory Vagal Interface: a bionic platform for internal organ modulation (VisceraLink)

  Medizinische Universitaet Wien· Wien, Austria· EU contribution €2,210,625· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Metabolic disease heterogeneity definition, prevention and remission with targeted interventions (MEDIculous REMeDy)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €4,437,236· until Dec 2030· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Switzerland· EU contribution €3,885,022· until Dec 2030· 9 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 4,137 running projects, newest first. Listed amounts together: US$2.5bn + €430.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT07553299· Verdiva Bio Dev Limited· Updated 13 Oct 2026

  “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”Registry text, quoted unchanged. Source

• Terminated

  RESCUE: Discontinuation of GLP-1

  NCT07190794· Boston Scientific Corporation· Updated 24 Jul 2026

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Medical College of Wisconsin· Updated 13 Jul 2026

  “no grant approved”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change

  NCT07097974· TCI Co., Ltd.· Updated 13 May 2026

  “based on an overall assessment of feasibility and strategic considerations”Registry text, quoted unchanged. Source

• Suspended

  Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

  NCT06171152· University of Chicago· Updated 30 Mar 2026

  “Study pending amendment”Registry text, quoted unchanged. Source

• Withdrawn

  The Effects of Semaglutide on Body Composition and Performance in Military Personnel

  NCT06468748· United States Army Research Institute of Environmental Medicine· Updated 19 Dec 2025

  “lack of funding”Registry text, quoted unchanged. Source

• Terminated

  A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

  NCT06000891· Zealand Pharma· Updated 25 Apr 2025

  “Decision by Sponsor; LSLV was completed on 21-Mar-2025 as planned.”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

  NCT06515418· BioAge Labs, Inc.· Updated 13 Mar 2025

  “Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

  NCT04885634· Axel Brandes· Updated 3 Nov 2023

  “Not received funding.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

  NCT07517042· Shanghai Zhongshan Hospital· Source

• 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor

  NCT07929233· Portuguese Oncology Institute, Coimbra· Source

• Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  NCT07830329· Regeneron Pharmaceuticals· Source

• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

  NCT06162715· Vanderbilt University Medical Center· Source

• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· AstraZeneca· Source

• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Amgen· Source

• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Regeneron Pharmaceuticals· Source

• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Pfizer· Source

• A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Pfizer· Source

• A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 10
• Mendelian Randomization Analysis 180
• CRISPR-Cas Systems 7
• Gene Expression Profiling 144
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 127
• Metabolomics 191
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 26
• Magnetic Resonance Imaging 258
• Machine Learning 155
• Deep Learning 20
• Cohort Studies 1014
• Genome-Wide Association Study 203

• Impact of Clinical Pharmacist Integration on Weight Management and Transplant Eligibility Among Patients With End-Stage Kidney Disease With Obesity.

  J Am Coll Clin Pharm, Dec 2026

• Compliance to National Cancer Grid of India Guidelines for Locally Advanced Cervical Cancer: Results From a Multicentric Observational Cohort in India.

  JCO Glob Oncol, Nov 2026

• Body composition and risks of head and neck cancers: evidence from a large-scale population-based cohort.

  Cancer Causes Control, Nov 2026

• Associations between biomarkers of vitamin K and cardiovascular disease risk factors: the role of lipids.

  Eur J Nutr, Nov 2026

• Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study.

  PLoS Med, Nov 2026

• Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort.

  J Korean Med Sci, Nov 2026

• Weight Trajectories in Virally Suppressed People With HIV Compared With Matched People Without HIV, and Predictors of Weight Gain: A 3-Year Cohort Study From the US TRIO Healthcare Network.

  J Acquir Immune Defic Syndr, Nov 2026

• A retrospective analysis of health care utilization and costs by body mass index category among adults with, or at risk of, cardiovascular disease.

  J Manag Care Spec Pharm, Nov 2026

• Exclusive and Any Breastfeeding, Infant Formula Feeding, and Childhood Growth.

  Pediatrics, Nov 2026

• Skinfolds in nulliparous women and their association with pregnancy complications: a multicenter cohort study in Brazil.

  Rev Bras Ginecol Obstet, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.